Normal colour vision (trichromacy) refers to vision that uses all three types of light cones. People with defected trichromatic vision will be colour blind to some extent and these conditions are called anomalous trichromacy. Three types anomalous trichromacy ( one type of cone perceives light slightly) :
1. Protanomaly – phenotype: reduced sensitivity to red light
2. Deuteranomaly - phenotype: reduced sensitivity to green light
3. Tritanomaly – phenotype: reduced sensitivity to blue
People can also have color blindess as the result of mutation, when loss of function of one cone occurs. This condition is called dichromacy. If there is complete color blindness or monochromacy, the person can’t distinguish any color from grey.
Color blindness is an inherited genetic disorder resulted from mutations on the X chromosome.
Yes it does because the human brain development is created through environmental and genetic influences
Codons that code for the same amino acid are termed synonyms, Silent mutations are base substitutions that result in no change of the amino acid or amino acid functionality when the altered messenger RNA (mRNA) is translated.
Answer:
Thermosensitive liposomes (TSL) are promising tools used to deliver drugs to targeted region when local hyperthermia is applied (∼40–42°C) which triggers the membrane phase transformation from a solid gel-like state to a highly permeable liquid state. Selective lipid components have been used to in TSL formulations to increase plasma stability before hyperthermia and speed drug release rate after. Two generations of TSL technology have been developed. The traditional thermal sensitive liposomes (TTSL) have utilized DPPC and DSPC as a combination. The second generation, lysolipid thermally sensitive liposomes (LTSL) technology, has been developed with incorporation of lysolipids that form stabilized defects at phase transition temperature. LTSL maintains certain favorable attributes:
High percentage of lysolipids incorporation;
Minimum leakage for therapeutical drugs encapsulation;
Ultrafast drug release upon heating (3.5 times enhanced compared to TTSL). For example, ThermoDox, a commonly used LTSL drug for cancer, has been reported to release 100% of the encapsulated doxorubicin within 30s;
First and most successful formulation for intravascular drug release.
Explanation:
https://www.creative-biostructure.com/Lysolipid-Thermally-Sensitive-Liposomes-Production-612.htm
